言語を選択

CA125

CA125 詳細

英語名	Mucin-16	市販薬剤の数	0
治験薬の数	11	ターゲットの別称	Mucin-16 Short Isoform，Mucin-16 Long Isoform，Ovarian carcinoma antigen CA125，Ovarian cancer-related tumor marker CA125，MUC16，MUC-16，CA-125，Mucin 16， Cell Surface Associated，CA125，CA125 Ovarian Cancer Antigen，Mucin-16，CA-125 Antigen，FLJ14303
研究＆開発段階	Phase 3 Clinical

英語名	Mucin-16
ターゲットの別称	Mucin-16 Short Isoform，Mucin-16 Long Isoform，Ovarian carcinoma antigen CA125，Ovarian cancer-related tumor marker CA125，MUC16，MUC-16，CA-125，Mucin 16， Cell Surface Associated，CA125，CA125 Ovarian Cancer Antigen，Mucin-16，CA-125 Antigen，FLJ14303
市販薬剤の数	0
治験薬の数	11
研究＆開発段階	Phase 3 Clinical

CA125 製品リスト

属性
Protein (8)
製品ライブラリ
オンライン (8)
種
Human (3)Cynomolgus (2)Mouse (1)Rabbit (1)Rat (1)
タグ
Fc Tag & Avi Tag (2)His Tag (5)His Tag & Avi Tag (1)
マーカー
Biotin-labeled (3)Unconjugated (5)

製品番号	種	発現システム	製品説明
HOT CA5-H52H6	Human	HEK293	Human CA125 / MUC16 (13810-14451) Protein, His Tag, low endotoxin (MALS verified)
HOT CA5-H82F4	Human	HEK293	Biotinylated Human CA125 / MUC16 Protein, Fc,Avitag™
HOT CA5-H82F8	Human	HEK293	Biotinylated Human CA125 / MUC16 (13810-14451) Protein, Fc,Avitag™
CA5-M52H6	Mouse	HEK293	Mouse CA125 / MUC16 Protein, His Tag (MALS verified)
CA5-C52H8	Cynomolgus	HEK293	Cynomolgus CA125 / MUC16 Protein, His Tag, low endotoxin (MALS verified)
CA5-C82E9	Cynomolgus	HEK293	Biotinylated Cynomolgus CA125 / MUC16 Protein, His,Avitag™ (MALS verified)
CA5-R52H4	Rabbit	HEK293	Rabbit CA125 / MUC16 Protein, His Tag
CA5-R52H5	Rat	HEK293	Rat CA125 Protein, His Tag (MALS verified)

総数量8

CA125バックグランド

The CA125, also known as the MUC16, is a mucin protein that may be found in type I transmembrane or secreted forms that are used monitor the progress of epithelial ovarian cancer therapy. The CA 125 molecule is almost certainly a glycoprotein with a predominance of O-linkages. It is heterogeneous with regard to both size and charge, most likely due to continuous deglycosylation of side chains during its life-span in bodily fluids. It exists as a very large complex (perhaps as much as 4 million daltons) under natural conditions.

CA125分子の別称

CA125,CA-125,CA125MUC-16,FLJ14303,MUC16,mucin 16,mucin-16

治験薬に関する情報

英語名	研究コード	研究開発ステージ	会社	適応症	臨床試験
Oregovomab	B43.13	Phase 3 Clinical	Paladin Pharma	Abdominal Neoplasms; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms	詳細
EB-NK-FM (FRalpha/MUC16)	EB-NK-FM	Phase 2 Clinical	Beijing Biotech	Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Peritoneal Neoplasms	詳細
EB-NK-MM (MSLN/MUC16)	EB-NK-MM	Phase 2 Clinical	Beijing Biotech	Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Peritoneal Neoplasms	詳細
LBL-033	LBL-033	Phase 2 Clinical	Nanjing Leadsbiolabs Co Ltd	Neoplasms	詳細
REGN-5668	REGN-5668	Phase 2 Clinical	Regeneron Pharmaceuticals Inc	Endometrial Neoplasms; Fallopian Tube Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms	詳細
Ubamatamab	REGN-4018	Phase 2 Clinical	Regeneron Pharmaceuticals Inc	Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Fallopian Tube Neoplasms; Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms	詳細
PRGN-3005	PRGN-3005	Phase 1 Clinical	Precigen Inc	Esophageal Neoplasms; Fallopian Tube Neoplasms; Lymphoma, Non-Hodgkin; Ovarian Neoplasms; Peritoneal Neoplasms; Sarcoma; Uterine Cervical Neoplasms	詳細
GB-5267	GB-5267	Phase 1 Clinical	Generate Biomedicines Inc	Ovarian Neoplasms	詳細
HWK-016	HWK-016	Phase 1 Clinical	Wuxi Biologics Co Ltd	Endometrial Neoplasms; Ovarian Neoplasms; Uterine Cervical Neoplasms	詳細
JCAR-020	JCAR-020	Phase 1 Clinical	Eureka Therapeutics Inc, Juno Therapeutics Inc, Memorial Sloan Kettering Cancer Center	Solid tumours	詳細
Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy(Regeneron Pharmaceutical)	27T-51; 27T51	Phase 1 Clinical	Regeneron Pharmaceuticals Inc	Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Peritoneal Neoplasms	詳細

レビュー

E***e2025-08-07
0評価
Human CA125 / MUC16 (13810-14451) Protein, His Tag, low endotoxin (MALS verified)
We used Acro Biosystems' recombinant Human CA125 / MUC16 protein (Catalog #CA5-H52H6) as a target antigen for antibody screening and downstream validation. The protein was employed in both ELISA and FACS assays. In ELISA, we observed strong, dose-dependent binding with minimal background, which enabled clear differentiation of candidate clones. For FACS, we used the protein to confirm surface staining specificity on engineered cell lines, and the results were consistent and reproducible. I was particularly impressed with the proteins high purity.